Luo Xin Pharmaceuticals officially debuted A shares! 1 new anti-tumor drug approved for clinical treatment

Medical Network May 13 hearing May 12, Elohim Pharmaceutical announced that a subsidiary of Shandong Pharmaceutical Elohim Elohim Pharmaceutical Group Co., Ltd(Shandong Elohim) and Elohim Pharmaceutical (Shanghai) Ltd(referred to as the Hailuo Xin) declaration of a class of drugs LX-086 a clinical trials implied license of the State Food and Drug Administration, there is no similar domestic drugs marketIn addition, since May 12, shares of Chinese securities referred east tone changed to "Elohim medicine."basic situationdata show that the product is PI3Kα selective inhibitor intended for the treatment of advanced solid tumors, at present there is no domestic similar drugs on the marketConventional pan-PI3K inhibitor different, LX-086 specific for PI3K protein α subunit, better targetingLX-086 by inhibiting the PI3K-Akt-mTOR signaling pathway, thereby inhibiting excessive proliferation of tumor cells, the purpose of treatment of various solid tumors, while avoiding influence the normal function of other PI3K protein subunits, thereby reducing the risk of drug safetyTheon Hailuo Xin Shandong Elohim and in accordance with the SFDA on the "Publish chemicalclassification reform program notice" provisions of Category 1 chemical reporting clinical applications, indications for the use of in the treatment of advanced solid tumorsAccording to "People's Republic of China Drug Administration Law" and the relevant provisions of the State Food and Drug Administration review, LX-086 piece on the relevant requirements of drug registration, and agreed to conduct clinical trials in accordance with the plan submittedIn addition, the Elohim Pharmaceutical application and approved by the Shenzhen Stock Exchange since 2020, May 12, shares of Chinese securities east sound short changed "Elohim medicine", the English stock short changed "LuoxinPharmaceutical"Securities code unchanged (still 002 793)Up to now, the company's convertible bonds referred unchanged, Chinese is still referred to as "East sound Convertible Bonds", the English abbreviation is still "DOYIN-CB", bonds code is unchanged at "128,043."Elohim medicine at the fourteenth meeting of the third Board of Directors in 2020, the second extraordinary general meeting adopted the "Proposal of Changing the company name and stock short name of" Chinese company agreed to name from "Zhejiang East tone Pump Co., Ltd." to "Elohim Pharmaceutical Group Co., Ltd.", the English name of "ZhejiangDoyinPumpIndustryCo., Ltd." changed to "LuoxinPharmaceuticalsGroupStockCo., Ltd.", referred to by the company's securities " East tone shares "to" Elohim medicine" 2020 April 28, the company has made renewal of the Zhejiang Administration of the market "business license", the company name was changed to Elohim Pharmaceutical Group Co., Ltd Statistics show that in 2019 the shares of East sound implementation of major assets and issue shares to buy assets matters, the acquisition of 99.65476% of the shares of Shandong Elohim Pharmaceutical Group Co., Ltd After completion of this transaction, the company's main business major changes, the transition into manufacturing industry, the main business of pharmaceutical product development, production and sales white feather finishing meters Intranet Source: listed company announcements, dongfangcaifuwang